Reviewer’s report

Title: Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease

Version: 0 Date: 31 Aug 2017

Reviewer: Francesco Pichi

Reviewer's report:

Thanks for the opportunity to review this VKH paper. I have a few perplexities for the Authors to answer.

ABSTRACT

SRF is a standardized abbreviation for sub retinal fluid. It may be bit confusing, especially for a reader who quickly goes through the abstract to see if the paper may be valuable.

It appeared that all pt presented to the Authors at a mean of 25 days from start of VKH, so in the acute stage. However all developed fibrosis. This is not my experience. It makes me wonder about the treatment (which is not mentioned in the abstract).

BACKGROUND

Wee summarized VKH. The authors mention that visual prognosis is good and then talk about "long-term". The fibrosis (again, SRF is confusing as an abbreviation) is defined as "chronic" complication. After reading the abstract, this seems even more concerning. @ lines later in the Methods there is a mention of patients referred with acute VKH and fibrosis..

This section needs to be rewritten

METHODS

"acute uveitis stage with SRF" is a bit disconcerting and goes against what was mentioned before.

The type of FA machine used needs to be specified.

The Authors need to mention that a data on previous treatment were collected.
Also the paragraph about treatment (line 29 pag 6) seems a bit redundant: this is a retrospective study.

TPPV is not a standard abbreviation for pars plana bit: it's PPV.

RESULTS

Ten patients included out of how many? I am sure there were more that did not meet the inclusion criteria.

A sentence and/or table need to be added for the therapy dosage that the patient were on: it is a bit concerning that all developed complications under the care of the Authors, makes a reader worried about under-dosage.

I am not sure what "transfiguration" of the fibrosis is..

On a personal note, at this point of the manuscript I skipped though the figures, and I started to wonder if some of those "acute fibrotic" lesions were not actually iCNV. Since the Authors have FAs on them, as per methods, they need to be added. OCTA in VKH has now showed us a different new world about those fibrotic lesions. Figure 1H, 3C, 3B have a neovascular appearance..

DISCUSSION and CONCLUSION

Needs to be rewritten according to the point above

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal